Welcome to our dedicated page for Oncocyte Corporation SEC filings (Ticker: OCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncocyte Corporation SEC filings, including later reports filed under the Insight Molecular Diagnostics Inc. name, document a molecular diagnostics issuer focused on transplant monitoring and oncology-related testing. The filings record financial results and material-event reporting for a company commercializing assays such as GraftAssure, VitaGraft, DetermaIO and DetermaCNI.
Governance filings cover annual meeting votes, director elections, auditor ratification, executive compensation advisory matters, and amendments to the company’s equity incentive plan. The records also address common-stock voting mechanics, share authorization under incentive plans, capital structure, and other public-company reporting obligations.
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is registering 2,716,859 additional shares of common stock for its Amended and Restated 2018 Equity Incentive Plan. These shares support stock-based awards for employees, directors, and other service providers.
The total comes from board- and stockholder-approved plan increases of 2,750,000 shares, less 33,141 shares already underlying granted awards that are excluded from this registration. The newly registered shares include 792,683 shares tied to restricted stock units, 262,000 shares underlying stock options, and 1,662,176 shares reserved for future equity awards.
The filing also restates the company’s indemnification protections for directors, officers, employees, and agents under California law and confirms that key officers and directors have signed the registration statement, authorizing the use of these shares under the plan.
Insight Molecular Diagnostics Inc. (f/k/a Oncocyte) reported a noticeable uptick in commercial activity with net revenue of $518,000 for the quarter ended June 30, 2025 versus $104,000 a year earlier, and $2.656 million for the six months versus $280,000. Revenue growth was driven primarily by laboratory services and initial sales of the GraftAssureIQ kitted product.
Results show widening losses: a net loss of $9.742 million in the quarter (six-month loss of $16.413 million), as operating expenses rose to $10.192 million for the quarter, including a $2.804 million charge for the change in fair value of contingent consideration. Liquidity improved materially following a February 2025 registered offering that raised gross proceeds of approximately $29.1 million (net proceeds ~$28.7 million), leaving cash and cash equivalents of $24.3 million and combined cash plus restricted cash of $26.0 million at period end.
Operational and strategic developments include a corporate name and ticker change to IMDX and headquarters relocation to Nashville, an ongoing strategic partnership and investment with Bio-Rad, and a boosted Medicare reimbursement rate of $2,753 per result for GraftAssureCore. Significant noncurrent contingent consideration of $40.933 million and an accumulated deficit of $366.95 million remain on the balance sheet. Management concluded there is no substantial doubt about going concern for at least the next twelve months.
Insight Molecular Diagnostics Inc. filed a current report to state that it released a press release with its financial results for the six months ended June 30, 2025. The company explains that the press release, dated August 11, 2025 and attached as Exhibit 99.1, contains details on its results of operations and financial condition for that period. The information in this section is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings unless specifically referenced.